Etanercept formulations stabilized with sodium chloride
The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
1. A syringe or injector pen containing a single dose of an aqueous pharmaceutical composition comprising about 25 to about 75 mg/ml etanercept and a stabilizing composition comprising about 3 to 5 wt. % of sucrose, sodium chloride, and an aqueous buffer, wherein the aqueous etanercept composition is free of arginine, wherein the single dose is 1 mL, wherein the aqueous pharmaceutical composition elicits long term storage stability as characterized by at least one of:
SEC analysis at M 3 or T 2 or T 4 of: monomer content greater than 90%;
aggregates content of less than 3 wt. %; and
fragment 3 content less than 5 wt. %,
wherein the aqueous pharmaceutical composition has no more than, on average, about 10,000 subvisible particles per mL having a size greater than 5 μm.
2. The syringe or injector pen of claim 1 , wherein the aqueous pharmaceutical composition has a pH of about 6.0 to about 6.6.
3. The syringe or injector pen of claim 1 , wherein etanercept is at a concentration of 50 mg/ml.
4. The syringe or injector pen of claim 1 , wherein the aqueous buffer is a citrate buffer.
5. The syringe or injector pen of claim 1 , wherein the aqueous pharmaceutical composition elicits long term storage stability as characterized by: an HIC analysis at M 3 or T 2 or T 4 wherein the amount of the aqueous pharmaceutical composition represented by peak 2 of the HIC chromatogram is greater than or equal to 95 wt. %; and wherein, if peak 3 is present on the HIC chromatogram, the amount of the composition represented by peak 3 is less than 3 wt. % or equal to about 3 wt. %.
6. The syringe or injector pen of claim 1 , wherein the aqueous composition elicits long term storage stability as characterized by at least one of: HIC analysis at M 3 or T 2 or T 4 wherein the amount of the composition represented by peak 1 of the HIC chromatogram is less than 3 wt. %; the amount of the composition represented by peak 2 of the HIC chromatogram is greater than 80 wt. %; and the amount of the composition represented by peak 3 of the HIC chromatogram is less than 20 wt. %.
7. The syringe or injector pen of claim 1 , wherein the aqueous composition is free of cysteine.
8. A syringe or injector pen containing a single dose of an aqueous composition consisting of about 50 mg/ml of etanercept stabilized by about 3 to 5 wt. % of sucrose, sodium chloride, sodium citrate, an aqueous buffer, and glycine or lysine.
9. The syringe or injector pen of claim 8 , wherein the aqueous pharmaceutical composition elicits long term storage stability as characterized by at least one of:
SEC analysis at M 3 or T 2 or T 4 of: monomer content greater than 90%;
aggregates content of less than 3 wt. %; and
fragment 3 content less than 5 wt. %.
10. A syringe or injector pen containing a single dose of an aqueous composition consisting of about 50 mg/ml of etanercept stabilized by about 3 to 5 wt. % of sucrose, sodium chloride, sodium citrate, an aqueous citrate buffer, and glycine or lysine.
11. The syringe or injector pen of claim 10 , wherein the aqueous composition consists of about 50 mg/ml of etanercept stabilized by about 3 to 5 wt. % of sucrose, sodium chloride, sodium citrate, an aqueous citrate buffer, and lysine.
12. A method of treating a subject suffering from rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, a psoriasis, or atopic dermatitis comprising injecting the subject with the syringe or injector pen of claim 1 .
13. The method of claim 12 , wherein the etanercept-containing protein mixture contains less than 5 wt. % incorrectly folded etanercept.
14. The method of claim 12 , wherein the aqueous pharmaceutical composition has aggregates content of less than 3 wt. %.
15. The method of claim 12 , wherein 25-100 mg etanercept is administered to the subject.
16. The method of claim 12 , wherein the injecting is subcutaneous.
17. A method of treating a subject suffering from rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, a psoriasis, or atopic dermatitis comprising injecting the subject with the syringe or injector pen of claim 8 .
18. A method of treating a subject suffering from rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, a psoriasis, or atopic dermatitis comprising injecting the subject with the syringe or injector pen of claim 10 .
19. A method of treating a subject suffering from rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, a psoriasis, or atopic dermatitis comprising injecting the subject with the syringe or injector pen of claim 11 .